Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The management team will conduct virtual investor meetings on December 2. A pre-recorded fireside chat presentation is available for streaming on Ocular Therapeutix's investor website, accessible for 90 days. The company focuses on innovative therapies for eye diseases, with FDA-approved DEXTENZA for ocular inflammation and ongoing clinical trials for treatments targeting glaucoma and dry eye disease.
Ocular Therapeutix (NASDAQ:OCUL) announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting held from November 13-15, 2020. Highlights include interim Phase 1 data for OTX-TKI, demonstrating safety and biological activity in wet AMD patients. The company also showcased DEXTENZA, emphasizing its efficacy in post-cataract inflammation. Additional studies presented include real-world patient experiences with DEXTENZA, indicating high satisfaction rates. These advancements underline Ocular Therapeutix's commitment to innovative ophthalmic therapies.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in two upcoming conferences. The Raymond James SMID Cap Company Showcase will take place on November 13, 2020, featuring one-on-one investor meetings. The Jefferies Virtual London Healthcare Conference is set for November 19, 2020, including a fireside chat at 5:35 PM GMT. Interested investors can contact their representatives for meetings, and a live webcast of the fireside chat will be accessible via the company's website. Ocular Therapeutix develops innovative eye therapies using proprietary technology.
Ocular Therapeutix (NASDAQ:OCUL) announced the acceptance of a permanent Category I Current Procedural Terminology (CPT) code for drug-eluting intracanalicular inserts, including DEXTENZA. This change, effective January 1, 2022, replaces the current Category III CPT code, enhancing reimbursement and coverage across payers. The decision validates DEXTENZA's novel administration method and supports other pipeline products. The CPT code aims to standardize payments for the procedure in both ASC and physician office settings, marking a significant milestone for Ocular Therapeutix and its products.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) has entered a license agreement with AffaMed Therapeutics for the development and commercialization of DEXTENZA® and OTX-TIC in Greater China, South Korea, and ASEAN markets. DEXTENZA is approved for post-surgical ocular inflammation and is being studied for allergic conjunctivitis, while OTX-TIC targets glaucoma. Ocular Therapeutix will receive $12 million upfront and could earn up to $91 million in milestone and support payments along with tiered royalties. The collaboration aims to leverage AffaMed's regional presence in a rapidly growing market, projected at $5 billion in sales.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its third quarter financial results will be reported on November 5, 2020. The company will hold a live conference call at 4:30 p.m. ET to discuss the results and provide a business update. Ocular Therapeutix specializes in innovative eye therapies and has FDA-approved products including DEXTENZA for ocular inflammation post-surgery. Current clinical trials include OTX-TIC, OTX-CSI, and OTX-TKI, with collaborations on extended-delivery formulations for retinal diseases.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced a public offering of 7,180,000 shares at $9.75 each, aiming for gross proceeds of approximately $70 million. The underwriters have a 30-day option to purchase an additional 1,077,000 shares. Close date is expected around October 16, 2020. The offering is registered under a previously effective shelf registration statement. This funding may support Ocular Therapeutix's innovative therapies for eye conditions, including DEXTENZA®, its FDA-approved drug.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) has initiated an underwritten public offering of its common stock. The company plans to grant the underwriters an option to purchase up to an additional 15% of the shares sold. All shares in this offering are being sold by the company, with market conditions influencing the completion timeline. The offering is based on a previously effective shelf registration statement with the SEC. Jefferies LLC and Piper Sandler & Co. are the joint book-running managers for the offering.
Ocular Therapeutix (NASDAQ: OCUL) reported preliminary third quarter 2020 net product revenue of $5.8 to $5.9 million, marking a sequential increase of over 250% from Q2. DEXTENZA accounted for $5.3 to $5.4 million of this total, achieving a 280% increase, while ReSure Sealant generated $0.5 million, up 150%. The company noted significant growth in DEXTENZA sales with nearly 10,000 billable units sold, reflecting a recovery in surgical volumes despite COVID-19's impact. Q3 financial results will be detailed on November 5, 2020.
Ocular Therapeutix (NASDAQ:OCUL) has granted a non-statutory stock option for 350,000 shares of common stock to new employee Philip C. Strassburger to incentivize his employment commencement. The option, effective October 5, 2020, has an exercise price of $8.42 per share, matching the closing stock price on that date. It features a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was independently approved by Ocular's Compensation Committee.